John Rim, CEO of Samsung Biologics, said in a New Year's address on the 2nd that the company will strengthen its position as a trusted contract development and manufacturing organization (CDMO) partner and will expand production capacity, portfolio, and global bases to solidify an ultra-wide competitive edge.
John Rim said that the environment surrounding the company this year will be tough and a high standard will be required on every front, adding that customer satisfaction cannot be overstated. He went on to say that quality is the foundation of the bio industry, which deals with life, and must be upheld without compromise under any circumstances, and that the company will streamline operations with artificial intelligence (AI) and invest in talent development to build employee capabilities.
Rim said the company must eliminate unnecessary complexity through simplification and increase the speed of decision-making and execution, adding that it must secure consistent quality at all times through standardization. He also said the company should pursue a growth strategy grounded in scalability to respond flexibly to rapidly changing markets and customer demands.
John Rim said the company completed a spin-off last year, secured a site for the third bio campus in Songdo, and acquired a plant in Rockville, U.S., adding that it will advance its antibody-drug conjugate (ADC) and Organoid (mini organ) businesses to develop them into key pillars supporting future growth. He continued that this year marks the 15th anniversary of the company's founding and the Year of the Red Horse, and, like a horse symbolizing tireless passion and drive, he hopes the company will leap toward its goal of becoming the No. 1 global CDMO.